Single answer
Is Alterity Therapeutics Limited (ATHE) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
No analyst target data available for this ticker.
Company snapshot
A quick overview of the business and its public profile.
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease Huntington disease Parkinsons disease and other neurological disorders in Australia The companys lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinsons disease It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimers disease The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019 Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne Australia
Website: https://alteritytherapeutics.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.14 and is down -0.0800 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: -68.93. Net profit margin: -223.35%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Alterity Therapeutics Limited is $274,928. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
On Alterity Therapeutics Limited, 2015-12-31 had a stock price of $43.20. If you invested back then, your return now would be a loss of $40.12 per share or 92.87%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.
No analyst target data available for this ticker.